Prostate cancer is a major cause of male cancer death in Western nations. Tumour development/progression is dependent on interactions between tumour cells and neighbouring stromal fibroblasts. The medical University of Innsbruck is investigating the therapeutic potential of targeting the enzyme NADPH oxidase 4 (Nox4), which plays a central role in stromal-tumour cell crosstalk in prostate cancer.
Eingereicht von: Priv. Doz. Dr. Natalie Sampson
Firma/Universität: Medical University of Innsbruck
Kooperationspartner: Genkyotex S.A.
Added value of collaboration: To closely mimic human prostate cancer, we employ primary human cells/tissue specimes of consenting prostate cancer patients undergoing surgical removal of the prostate. This collaboration thus provides Genkyotex with a unique opprtunity to gain important pre-clinical information on the potential application of GKT831 for research purposes, offers an additional approach to complement genetic-based studies of Nox4 inhibition, thereby increasing the robustness, throughput and translational-relevance of research findings.
Social benefit: The collaboration project addresses an unmet need for improving treatment of prostate and other cancer patients: targeting the tumor microenvironment in addition to tumor cells. Elevated Nox4 expression is observed not only in prostate cancer but also in non-prostate tumours and numerous fibrotic diseases. Indeed, GKT831 is already undergoing phase II clinical trials for several fibrotic pathologies. Data generated herein are thus expected to be of significant relevance to a broad spectrum of patients and clinicians and may lead to improved disease management and treatment strategies.